^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SNC103
i
Other names: SNC103, CAR-NK-CD19 cells, cord blood derived anti-CD19 CAR-engineered NK cells, anti-CD19 chimeric antigen receptor(CAR)-modified NK cells, F01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Simnova Bio
Drug class:
CD19 inhibitor, NK cell stimulant
Related drugs:
6ms
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
New P1 trial
|
cyclophosphamide • SNC103
10ms
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd. | Initiation date: Jan 2024 --> Apr 2024
Trial initiation date
|
cyclophosphamide • SNC103
11ms
F01 in the Treatment of Autoimmune Diseases (clinicaltrials.gov)
P1, N=20, Recruiting, RenJi Hospital
New P1 trial
|
cyclophosphamide • fludarabine IV • SNC103
11ms
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
New P1 trial
|
cyclophosphamide • SNC103
2years
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=2, Completed, Shanghai Simnova Biotechnology Co.,Ltd. | Recruiting --> Completed | N=21 --> 2 | Trial completion date: Jul 2024 --> Nov 2022 | Trial primary completion date: Jul 2023 --> Nov 2022
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • SNC103
2years
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=21, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
New P1 trial
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • SNC103
almost4years
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies (clinicaltrials.gov)
P1, N=27, Recruiting, Wuhan Union Hospital, China
Clinical • New P1 trial
|
CD19 (CD19 Molecule)
|
fludarabine IV • SNC103
Share via
